Fibrin glue system for adjuvant brachytherapy of brain tumors with 188Re and 186Re-labeled microspheres

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 65, Issue 3, 2007, Pages 282-288

  Häfeli, Urs O ^a   Pauer, Gayle J ^b   Unnithan, Jaya ^b   Prayson, Richard A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Brachytherapy; Brain tumor; Fibrin glue; Microspheres; Rhenium radioisotopes

Indexed keywords

FIBRIN GLUE; MICROSPHERE; RHENIUM 186; RHENIUM 188;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA RADIATION; BRACHYTHERAPY; BRAIN TUMOR; DOSIMETRY; FILM DOSIMETER; GLIOBLASTOMA; HALF LIFE TIME; NEUTRON ACTIVATION ANALYSIS; NONHUMAN; RAT; SURVIVAL; TUMOR LOCALIZATION; TUMOR RECURRENCE;

ADHESIVENESS; ANIMALS; BRACHYTHERAPY; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FIBRIN TISSUE ADHESIVE; GELS; GLIOBLASTOMA; ISOTOPES; MICROSPHERES; NEOPLASM TRANSPLANTATION; RADIATION DOSAGE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RATS; RATS, SPRAGUE-DAWLEY; RHENIUM; TIME FACTORS;

EID: 33847297571     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.10.016     Document Type: Article

References (39)

1. American Cancer Society cancer statistics; http://www.cancer.org/docroot/STT/STT_0.asp (accessed February 22, 2006).
2. Canadian cancer statistics; http://www.cancer.ca/ccs/internet/standard/0,3182,3278_12851__langId- en,00.html (accessed February 22, 2006).
3. Young R.F. Radiosurgery for the treatment of brain metastases. Semin. Surg. Oncol. 14 (1998) 70-78
4. Fisher P.G., and Buffler P.A. Malignant gliomas in 2005: where to go from here?. JAMA 293 (2005) 615-617
5. Berg G., Blomquist E., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol. 42 (2003) 582-588
6. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Lancet 345 (1995) 1008-1012
7. Laws E.R., Parney I.F., Huang W., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 99 (2003) 467-473
8. Backlund E.O. Colloidal radioisotopes as part of a multi-modality treatment of craniopharyngiomas. J. Neurosurg. Sci. 33 (1989) 95-97
9. Vitaz T.W., Warnke P.C., Tabar V., and Gutin P.H. Brachytherapy for brain tumors. J. Neurooncol. 73 (2005) 71-86
10. Larson D.A., Suplica J.M., Chang S.M., et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol. 6 (2004) 119-126
11. Tatter S.B., Shaw E.G., Rosenblum M.L., et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J. Neurosurg. 99 (2003) 297-303
12. Sierra D.H. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J. Biomater Appl. 7 (1993) 309-352
13. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. (1994) 58-63
14. MacGillivray T.E. Fibrin sealants and glues. J. Card Surg. 18 (2003) 480-485
15. Nishimoto K., Yamamura K., Fukase F., et al. Subcutaneous tissue release of amikacin from a fibrin glue/polyurethane graft. J. Infect. Chemother 10 (2004) 101-104
16. Moon M.C., Molnar K., Yau L., and Zahradka P. Perivascular delivery of losartan with surgical fibrin glue prevents neointimal hyperplasia after arterial injury. J. Vasc. Surg. 40 (2004) 130-137
17. Shireman P.K., and Greisler H.P. Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue. J. Vasc. Surg. 31 (2000) 936-943
18. Erzurum V.Z., Bian J.F., Husak V.A., et al. R136K fibroblast growth factor-1 mutant induces heparin-independent migration of endothelial cells through fibrin glue. J. Vasc. Surg. 37 (2003) 1075-1081
19. Cheng H., Huang S.S., Lin S.M., et al. The neuroprotective effect of glial cell line-derived neurotrophic factor in fibrin glue against chronic focal cerebral ischemia in conscious rats. Brain Res. 1033 (2005) 28-33
20. Conzone S.D., Häfeli U.O., Day D.E., and Ehrhardt G.J. Preparation and properties of radioactive rhenium glass microspheres intended for in-vivo radioembolization therapy. J. Biomed. Mater Res. 42 (1998) 617-625
21. Merkli A., Heller J., Tabatabay C., and Gurny R. Gamma sterilization of a semi solid poly(ortho ester) designed for controlled drug delivery - validation and radiation effects. Pharm. Res. 11 (1994) 1485-1491
22. Klassen N.V., van der Zwan L., and Cygler J. Gafchromic MD-55: investigated as a precision dosimeter. Med. Phys. 24 (1997) 1924-1934
23. Häfeli U.O. Chapter 18: Radiolabeled Magnetic Microcapsules for Magnetically Targeted Radionuclide Therapy. In: Arshady R. (Ed). Microspheres, Microcapsules and Liposomes: Radiolabeled and Magnetic Particulates in Medicine and Biology vol. 3 (2001), Citus Books, London 559-584
24. G. Marx, Fibrin applicator pistol, U.S. Patent No. 6,863,660 B2 (March 8, 2005).
25. T.P. Zimmerman, C.A. Dadd, G.A. Baumbach, Method and device for delivering fibrin glue, U.S. Patent No. 6,121,422 (September 19, 2000).
26. Ron E.S., Bromberg L., Luczak S., et al. Smart hydrogel: a novel mucosal delivery system. Proc. Int. Symp. Control Rel. Bioact. Mater. 24 (1997) 407-408
27. Nori D., Li X., and Pugkhem T. Intraoperative brachytherapy using Gelfoam radioactive plaque implants for resected stage III non-small cell lung cancer with positive margin: a pilot study. J. Surg. Oncol. 60 (1995) 257-261
28. Duggirala S., and DeLuca P.P. Buffer uptake and mass loss characteristics of freeze-dried cellulose and alginate devices. PDA J. Pharm. Sci. Technol. 50 (1996) 297-305
29. 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl. Med. Commun. 27 (2006) 223-229
30. Wang S.J., Lin W.Y., Hsieh B.T., et al. Rhenium-188 sulphur colloid as a radiation synovectomy agent. Eur. J. Nucl. Med. 22 (1995) 505-507
31. Grillenberger K.G., and Reske S.N. Improved Synthesis and In Vitro Stability Test of Rhenium-188 Labeled Radiopharmaceuticals for Potential Use in Radiation Synovectomy. In: Bergmann H., Kroiss A., and Sinzinger H. (Eds). Radioactive Isotopes in Clinical Medicine and Research. XXII (1997), Birkhäuser Verlag, Basel, Switzerland 433-436
32. Wunderlich G., Pinkert J., Andreeff M., et al. Preparation and biodistribution of rhenium-188 labeled albumin microspheres B20: a promising new agent for radiotherapy. Appl. Radiat. Isotopes 52 (2000) 63-68
33. Häfeli U., Pauer G., Failing S., and Tapolsky G. Radiolabeling of magnetic particles with rhenium-188 for cancer therapy. J. Magn. Magn. Mater 225 (2001) 73-78
34. Cao J., Wang Y., Yu J., et al. Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy. J. Magn. Magn. Mater 277 (2004) 165-174
35. +. Nucl. Med. Commun. 26 (2005) 453-458
36. Hall E.J. Radiobiology for the Radiologist. 6th ed. (2000), JB Lippincott, Philadelphia
37. Ling C.C., Spiro I.J., and Mitchell J. The variation of OER with dose rate. Intl. J. Radiat. Oncol. Biol. Phys. 11 (1985) 1367-1373
38. Menei P., Boisdron-Celle M., Croue A., et al. Effect of stereotactic implantation of biodegradable 5-fluorouracil loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 39 (1996) 117-124
39. Fournier E., Passirani C., Montero-Menei C., et al. Cancer 97 (2003) 2822-2829